Clonorchiasis Infections and Infestations Clonorchiasis
Conditions
Interventions
Current interventions as of 14/08/2012:
The intervention consists of four treatments, all the medicine is administered orally to each person
1. Multiple-dose praziquantel serves as control, and the t
Sponsors
The National Institute of Parasitic Diseases (China)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 14/08/2012: Eligible patients are residents of Hunan province aged 15 to 65 years who have Clonorchis sinensis infections, both sexes. Previous inclusion criteria until 14/08/2012: Eligible patients are residents of Guangdong province aged 2 years and above who had Clonorchis sinensis infections, both sexes
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women 2. Presence of any abnormal medical condition, such as heart disease, high blood pressure, severe malnutrition, severe liver and kidney disease, psychiatric and neurologic disorders 3. Use of praziquantel , tribendimidine, albendazole and mebendazole or any anthelminthic treatment within the past month 4. Enrolled in any other clinical investigation during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Egg reduction rate (ERR) and cure rate (CR), measured using the Kato-Katz stool examination method 2. Adverse reactions, measured using a standardised questionnaire. The intensity of adverse events was graded as mild, moderate, severe and serious Assessed at 4 weeks after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| All the participants who are to receive the tribendimidine treatment will accept checks of blood, urine, electrocardiogram, liver function and kidney function before and after the treatment. The abnormal indexes will be supervised and recorded. | — |
Countries
China
Outcome results
None listed